Close Menu

You may find more results for this query on our sister sites: GenomeWeb and 360Dx.

Home › Diagnostics › Molecular Diagnostics › FLT3-Targeted Treatment Extends Advanced AML Survival in ADMIRAL Trial

FLT3-Targeted Treatment Extends Advanced AML Survival in ADMIRAL Trial

Oct 31, 2019
|
staff reporter

NEW YORK – A University of Pennsylvania-led team has published details from a Phase III trial demonstrating that the FLT3 inhibitor gilteritinib (Astellas Pharma's Xospata) can significantly extend average survival in individuals with relapsed or refractory forms of acute myeloid leukemia (AML) containing FLT3 gene mutations.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Jul
16
Featured Webinar

Exploring Tumor Tissue Architecture and Immune Response with Digital Spatial Profiling

Join this webinar to learn how spatial resolution of gene expression in tumor tissue reveals new insights in biomarker discovery and therapeutic response. 

Jul
23
Featured Webinar

Clinical Utility of Liquid Biopsy for the Detection of T790M to Guide Lung Cancer Treatment Strategy

This webinar will discuss a study that set to assess the efficacy and safety of osimertinib in EGFR T790M positive non-small cell lung cancer (NSCLC) patients identified by using plasma sample and cobas EGFR Mutation test v2. This is the first prospective study to use liquid biopsy upfront to evaluate osimertinib efficacy.

Aug
25
Featured Webinar

Liquid Biopsy-based Molecular Risk Stratification of ALK-mutated Lung Cancer Patients

Non-small cell lung cancer (NSCLC) patients with ALK rearrangements are treated with tyrosine kinase inhibitors (TKIs), which often leads to prolonged overall survival. However, treatment resistance will almost inevitably occur, and the disease remains incurable.

What's Popular?

In Cancer

  1. Precision Oncology Trials Still Enroll Mostly White Patients Despite Initiatives, Calls to Diversify

    Premium

  2. Cancer AI Startup Nucleai Raises $6.5M in Series A Financing

  3. EMA Accepts Daiichi Sankyo's Application for Enhertu in HER2-Positive Breast Cancer

  4. New I-SPY 2 Trial Arm to Evaluate Byondis' Antibody-Drug Conjugate in HER2-Low Breast Cancer

  5. Menarini to Launch Trial Evaluating PI3K Inhibitor MEN1611 in Metastatic Colorectal Cancer

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.